We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Niraparib

By: Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®

Published In: Voice

Publication Date: 2020-02-25

Description

Niraparib (Zejula^®) was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Niraparib

Description

ONS Drug Education

Related Topics